THE PHENOMENON OF ?NO-REFLOW? ― A MODERN VIEW OF THE PROBLEM. THE PLACE BLOCKERS GLYCOPROTEIN IIb/IIIa RECEPTOR IN THE PREVENTION OF THIS CONDITION

For mechanical reperfusion using as primary percutaneous coronary intervention (PPCI) and at pharma-coinvasive strategy requires a clear compliance with the time intervals that is an important moment in the treatment of myocardial infarction-segment elevation ST (MI ST). However, it should be noted that a large proportion of patients who in the time frame set was performed reperfusion therapy with thrombolytic or PCI restoring blood flow is achieved only at the epicardial vessels, i.e. developed the so-called phenomenon of ?no-reflow? or the phenomenon of ?no blood flow recovery?. Proved that in the development of the state play a role once 4 pathogenetic factors that complicates diagnosis and treatment of the phenomenon of ?no-ref¬low?. Largest proven positive effect for preventing the development of the phenomenon of ?no-reflow? have blockers GP IIb/IIIa receptor.